Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$4.20 -3.9%	$3.24	$2.12 ▼ $5.80	$434.06M	1.97	1.50 million shs	2.51 million shs
JANX Janux Therapeutics	$26.40 -4.9%	$24.62	$22.48 ▼ $71.71	$1.64B	2.86	876,731 shs	908,736 shs
SDGR Schrodinger	$21.45 -0.9%	$21.94	$16.60 ▼ $28.47	$1.59B	1.58	926,705 shs	962,275 shs
VERA Vera Therapeutics	$23.05 -3.0%	$22.78	$18.53 ▼ $51.61	$1.52B	1.19	998,596 shs	756,175 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	-3.89%	+4.74%	+23.53%	+67.33%	+35.48%
JANX Janux Therapeutics	-4.86%	+4.97%	+16.20%	-11.08%	-39.88%
SDGR Schrodinger	-0.92%	+2.09%	+1.90%	-16.70%	-7.42%
VERA Vera Therapeutics	-2.99%	-3.23%	+10.18%	+8.27%	-34.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AQST Aquestive Therapeutics	1.2493 of 5 stars	3.5	3.0	0.0	0.0	0.0
JANX Janux Therapeutics	2.0118 of 5 stars	3.5	1.0	2.5	2.5	0.0
SDGR Schrodinger	1.8263 of 5 stars	3.4	1.0	1.9	1.7	0.6
VERA Vera Therapeutics	4.0861 of 5 stars	4.6	5.0	1.9	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	3.00	Buy	$10.14	141.50% Upside
JANX Janux Therapeutics	3.08	Buy	$91.89	248.06% Upside
SDGR Schrodinger	2.75	Moderate Buy	$32.75	52.68% Upside
VERA Vera Therapeutics	3.10	Buy	$65.00	182.00% Upside

Current Analyst Ratings Breakdown

Latest AQST, SDGR, JANX, and VERA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	SDGR Schrodinger	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $30.00
7/11/2025	JANX Janux Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
7/3/2025	SDGR Schrodinger	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$28.00
6/17/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/3/2025	VERA Vera Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/3/2025	VERA Vera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/2/2025	AQST Aquestive Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
6/2/2025	VERA Vera Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Sector Outperform ➝ Sector Outperform	$55.00 ➝ $65.00
6/2/2025	VERA Vera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $85.00
5/15/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/7/2025	VERA Vera Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$34.00 ➝ $26.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$57.56M	7.25	N/A	N/A	($0.66) per share	-6.36
JANX Janux Therapeutics	$10.59M	147.51	N/A	N/A	$19.49 per share	1.35
SDGR Schrodinger	$207.54M	7.58	N/A	N/A	$5.78 per share	3.71
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$9.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$44.14M	-$0.59	N/A	N/A	N/A	-100.02%	N/A	-50.31%	8/5/2025 (Estimated)
JANX Janux Therapeutics	-$68.99M	-$1.36	N/A	N/A	N/A	N/A	-9.29%	-8.89%	8/6/2025 (Estimated)
SDGR Schrodinger	-$187.12M	-$2.63	N/A	N/A	N/A	-83.39%	-44.74%	-26.29%	7/30/2025 (Estimated)
VERA Vera Therapeutics	-$152.15M	-$3.00	N/A	N/A	N/A	N/A	-40.59%	-34.54%	8/6/2025 (Estimated)

Latest AQST, SDGR, JANX, and VERA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	VERA Vera Therapeutics	-$0.82	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	JANX Janux Therapeutics	-$0.50	N/A	N/A	N/A	$0.30 million	N/A
8/5/2025	Q2 2025	AQST Aquestive Therapeutics	-$0.18	N/A	N/A	N/A	$11.32 million	N/A
7/30/2025	Q2 2025	SDGR Schrodinger	-$0.83	N/A	N/A	N/A	$52.03 million	N/A
5/12/2025	Q1 2025	AQST Aquestive Therapeutics	-$0.17	-$0.24	-$0.07	-$0.24	$12.23 million	$8.72 million
5/8/2025	Q1 2025	JANX Janux Therapeutics	-$0.43	-$0.38	+$0.05	-$0.38	$0.59 million	N/A
5/8/2025	Q1 2025	VERA Vera Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	N/A	N/A
5/7/2025	Q1 2025	SDGR Schrodinger	-$0.81	-$0.82	-$0.01	-$0.82	$54.60 million	$59.55 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	4.87	4.48
JANX Janux Therapeutics	N/A	58.47	58.47
SDGR Schrodinger	N/A	3.45	3.45
VERA Vera Therapeutics	0.10	27.68	27.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
JANX Janux Therapeutics	75.39%
SDGR Schrodinger	79.05%
VERA Vera Therapeutics	99.21%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	8.35%
JANX Janux Therapeutics	8.10%
SDGR Schrodinger	8.60%
VERA Vera Therapeutics	16.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	160	99.33 million	91.03 million	Optionable
JANX Janux Therapeutics	30	59.17 million	54.38 million	Optionable
SDGR Schrodinger	790	73.38 million	67.07 million	Optionable
VERA Vera Therapeutics	40	63.77 million	53.38 million	Optionable

AQST, SDGR, JANX, and VERA Headlines

Recent News About These Companies

Vera Therapeutics, Inc. (NASDAQ:VERA) Receives $65.00 Consensus PT from Analysts

July 18 at 2:37 AM | americanbankingnews.com

Startup targets orphan kidney disease with former Merck drug

July 17 at 2:38 PM | medcitynews.comM

Reviewing Celcuity (NASDAQ:CELC) and Vera Therapeutics (NASDAQ:VERA)

July 16 at 2:21 AM | americanbankingnews.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of "Buy" from Brokerages

July 15, 2025 | marketbeat.com

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 10, 2025 | globenewswire.com

Vera Therapeutics Reports Positive Phase 3 ORIGIN Trial Results for Atacicept in IgA Nephropathy

July 6, 2025 | msn.com

Vera Therapeutics Inc Class A Sustainability - Morningstar

July 5, 2025 | morningstar.comM

Vera Therapeutics director Enright buys shares worth $5.2m

June 27, 2025 | investing.com

Vor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in Funding

June 27, 2025 | msn.com

Vera Therapeutics (NASDAQ:VERA) Shares Gap Up Following Insider Buying Activity

June 26, 2025 | marketbeat.com

Insider Buying: Vera Therapeutics, Inc. (NASDAQ:VERA) Director Acquires 40,607 Shares of Stock

June 26, 2025 | insidertrades.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Director Patrick G. Enright Purchases 40,607 Shares

June 25, 2025 | marketbeat.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Director Patrick G. Enright Acquires 209,393 Shares

June 25, 2025 | marketbeat.com

Polycythemia Vera Market Set for Strong Growth Across Key Markets, Backed by Emerging Treatments and Epidemiological Trends | DelveInsight

June 24, 2025 | theglobeandmail.com

BAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsight

June 24, 2025 | finance.yahoo.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Buy" by Brokerages

June 20, 2025 | marketbeat.com

J.P. Morgan Reaffirms Their Buy Rating on Vera Therapeutics (VERA)

June 19, 2025 | theglobeandmail.com

Analysts Can't Get Enough of These Little-Known Biopharma Stocks (VERA)

...

June 12, 2025 | marketbeat.com

Vera Therapeutics Inc.

June 10, 2025 | barrons.com

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 9, 2025 | globenewswire.com

Otsuka, Vera stake their claims to IgAN treatment

June 9, 2025 | pharmaphorum.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST, SDGR, JANX, and VERA Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$4.20 -0.17 (-3.89%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$4.24 +0.04 (+0.95%)

As of 07/18/2025 07:58 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Janux Therapeutics NASDAQ:JANX

$26.40 -1.35 (-4.86%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$26.40 +0.01 (+0.02%)

As of 07/18/2025 06:53 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Schrodinger NASDAQ:SDGR

$21.45 -0.20 (-0.92%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$21.74 +0.29 (+1.33%)

As of 07/18/2025 07:57 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Vera Therapeutics NASDAQ:VERA

$23.05 -0.71 (-2.99%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$23.04 0.00 (-0.02%)

As of 07/18/2025 07:52 PM Eastern

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time